Inhibiting the osteocyte-specific protein sclerostin increases bone mass and fracture resistance in multiple myeloma

This study defines a therapeutic strategy superior to the current standard of care that will reduce fractures for patients with MM.

Source: Blood - June 29, 2017 Category: Hematology Authors: McDonald, M. M., Reagan, M. R., Youlten, S. E., Mohanty, S. T., Seckinger, A., Terry, R. L., Pettitt, J. A., Simic, M. K., Cheng, T. L., Morse, A., Le, L. M. T., Abi-Hanna, D., Kramer, I., Falank, C., Fairfield, H., Ghobrial, I. M., Baldock, P. A., Little Tags: Multiple Myeloma, Lymphoid Neoplasia Source Type: research